A New Goal for Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: Treatment-free Remission -Review.
10.7534/j.issn.1009-2137.2016.06.049
- Author:
Lan YANG
1
;
Bian-Hong WANG
2
;
Xiang-Shu JIN
1
;
Yu JING
1
;
Li YU
3
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853.
2. Department of Hematology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
3. Department of Hematology, Chinese PLA General Hospital, Beijing 100853. E-mail: chunhuiliyu @ yahoo.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2016;24(6):1883-1887
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitor (TKI) therapy significantly improved the prognosis and outcome of patients with chronic myeloid leukemia(CML). Long-term therapy of TKI drugs was often accompanied with financial burden and the rise of chronic adverse effects. At present, the treatment-free remission (TFR) has been gradually regarded as the new ultimate aim to the patients with long-term CML. In clinical trials, the patients with the therapy of imatinib stopping TKI treatment after acquired deep molecular reaction still maintained remission. Here, the research progress on discontinuation of TKI therapy and how to better grasp the safety of drug withdrawal strategy are reviewed. However, the radical cure of CML needs more further research.
